Mauro Schechter
Overview
Explore the profile of Mauro Schechter including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
127
Citations
11042
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Diaz R, Grangeiro A, Estevam D, Galinskas J, Dias D, Schechter M
J Acquir Immune Defic Syndr
. 2021 Oct;
89(2):e16.
PMID: 34629413
No abstract available.
12.
Granger L, Huettner I, Debeljak F, Kaleebu P, Schechter M, Tambussi G, et al.
AIDS
. 2021 Jun;
35(13):2073-2084.
PMID: 34127581
Objective: Development of immunogens that elicit an anti-HIV-1 broadly neutralizing antibody (bnAb) response will be a key step in the development of an effective HIV-1 vaccine. Although HIV-1 bnAb epitopes...
13.
Janes H, Brown M, Glidden D, Mayer K, Buchbinder S, McMahan V, et al.
PLoS One
. 2019 Sep;
14(9):e0222183.
PMID: 31536518
Introduction: Developing guidelines to inform the use of antiretroviral pre-exposure prophylaxis (PrEP) for HIV prevention in resource-limited settings must necessarily be informed by considering the resources and infrastructure needed for...
14.
Spinelli M, Glidden D, Anderson P, Gandhi M, McMahan V, Defechereux P, et al.
AIDS Res Hum Retroviruses
. 2019 May;
35(9):788-793.
PMID: 31119944
Bone mineral density (BMD) declines due to tenofovir-containing pre-exposure prophylaxis (PrEP) have varied among PrEP demonstration projects, potentially related to variable adherence. Characterization of BMD changes in highly adherent individuals,...
15.
Bekker L, Alleyne G, Baral S, Cepeda J, Daskalakis D, Dowdy D, et al.
Lancet
. 2018 Jul;
392(10144):312-358.
PMID: 30032975
No abstract available.
16.
Nachega J, Sam-Agudu N, Mofenson L, Schechter M, Mellors J
Clin Infect Dis
. 2018 May;
67(9):1469-1470.
PMID: 29718304
No abstract available.
17.
Schechter M
J Int AIDS Soc
. 2018 Feb;
21(2).
PMID: 29436779
Initiation of antiretroviral therapy is not a once in a lifetime opportunity. In some resource constrained settings financial limitations make it necessary to prioritize treatment initiation for some groups of...
18.
Glidden D, Mulligan K, McMahan V, Anderson P, Guanira J, Chariyalertsak S, et al.
Clin Infect Dis
. 2018 Feb;
67(3):411-419.
PMID: 29415175
Background: Antiretroviral drugs have been associated with changes in lipids, fat mass and dat distribution. Tenofovir disoproxil fumarate (TDF) has been shown to have a more favorable metabolic profile than...
19.
Molina J, Grund B, Gordin F, Williams I, Schechter M, Losso M, et al.
Lancet HIV
. 2018 Jan;
5(4):e172-e180.
PMID: 29352723
Background: Immediate initiation of antiretroviral therapy (ART) in asymptomatic adults with CD4 counts higher than 500 cells per μL, as recommended, might not always be possible in resource-limited settings. We...
20.
Nachega J, Sam-Agudu N, Mofenson L, Schechter M, Mellors J
Clin Infect Dis
. 2018 Jan;
66(10):1487-1491.
PMID: 29324994
Although significant progress has been made, the latest data from low- and middle-income countries show substantial gaps in reaching the third "90%" (viral suppression) of the UNAIDS 90-90-90 goals, especially...